Department of Urology, Fujita Health University School of Medicine, Toyoake, Japan.
Division of Urology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, The Thai Red Cross Society, Bangkok, Thailand.
Int J Urol. 2024 Apr;31(4):370-378. doi: 10.1111/iju.15377. Epub 2024 Jan 5.
To evaluate the safety and efficacy of robot-assisted radical cystectomy using an intracorporeal ileal conduit in older compared to younger patients.
We retrospectively analyzed 122 patients who underwent robot-assisted radical cystectomy with an intracorporeal ileal conduit at Fujita Health University Hospital and Fujita Health University Okazaki Medical Center between 2012 and 2022. Patients were categorized into two groups: older (age ≥ 75 years; n = 53) and younger (age < 75 years; n = 69). Perioperative outcomes, complications, recurrence-free survival, cancer-specific survival, and overall survival were compared between the cohorts.
The groups had no significant differences in perioperative outcomes, such as estimated blood loss, operative time, and blood transfusion rate. However, hospital stay was longer in the older patients than in the younger group (19 vs. 16 days; p < 0.001). The 30-day minor and major complication rates were 33.3% and 13.0%, respectively, for the younger group and 50.9% and 9.4% for the older group (p = 0.11). Urinary tract infection and bowel ileus were the most common complications in both groups. No significant differences were observed in recurrence-free survival, cancer-specific survival, and overall survival between the groups (p = 0.58, p = 0.75, and p = 0.78), and subgroup analysis in ≥cT3 revealed the older group tended to have poorer cancer-specific survival and overall survival (p = 0.07 and p = 0.01). Multivariate analysis indicated that older age was not associated with high-grade complications and cancer-specific survival.
Robot-assisted radical cystectomy with an intracorporeal ileal conduit is a safe and effective treatment option for older patients.
评估与年轻患者相比,老年患者行机器人辅助根治性膀胱切除术并采用腔内回肠导管的安全性和有效性。
我们回顾性分析了 2012 年至 2022 年期间在藤田保健卫生大学医院和藤田保健卫生大学冈崎医疗中心接受机器人辅助根治性膀胱切除术并采用腔内回肠导管的 122 例患者。患者分为两组:老年组(年龄≥75 岁;n=53)和年轻组(年龄<75 岁;n=69)。比较两组患者的围手术期结局、并发症、无复发生存率、癌症特异性生存率和总生存率。
两组患者在围手术期结局方面,如估计出血量、手术时间和输血率等方面无显著差异。然而,老年组患者的住院时间长于年轻组(19 天比 16 天;p<0.001)。年轻组患者 30 天内的轻微和主要并发症发生率分别为 33.3%和 13.0%,老年组患者分别为 50.9%和 9.4%(p=0.11)。尿路感染和肠梗阻是两组患者最常见的并发症。两组患者无复发生存率、癌症特异性生存率和总生存率均无显著差异(p=0.58、p=0.75 和 p=0.78),≥cT3 的亚组分析显示老年组患者癌症特异性生存率和总生存率较差(p=0.07 和 p=0.01)。多变量分析表明,年龄较大与高级别并发症和癌症特异性生存率无关。
机器人辅助根治性膀胱切除术并采用腔内回肠导管是老年患者安全有效的治疗选择。